Chronic treatment of African-American type 2 diabetic patients with α- glucosidase inhibition

Diabetes Care

Volumn 21, Issue 3, 1998, Pages 416-422

  Johnston, Peter S ^a,d   Feig, Peter U ^a   Coniff, Robert F ^a   Krol, Alice ^a   Kelley, David E ^b   Mooradian, Arshag D ^c  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIGLITOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; MALE; MICROALBUMINURIA; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CHOLESTEROL, LDL; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG EVALUATION; ENZYME INHIBITORS; FEMALE; GLUCOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMINO PYRANOSES; INSULIN; MALE; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD; SINGLE-BLIND METHOD; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0031937651     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.3.416     Document Type: Article

References (20)

1. Harris MI: Non-insulin-dependent diabetes mellitus in black and white Americans. Diabete Metab Rev 6:71-90, 1990
2. Chaiken RL, Banerji MA, Pasmantier R, Huey H, Hirsch S, Lebovitz HE: Patterns of glucose and lipid abnormalities in black NIDDM subjects. Diabetes Care 14:1036-1042, 1991
3. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. Ohkubo Y, Kishikawa H, Araki E, Miyota T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Prac 28:103-117, 1995
5. American Diabetes Association: Implications of the Diabetes Control and Complications Trial. Diabetes Care 16:1517-1520, 1993
6. Hoffman J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 17:561-566, 1994
7. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS: The efficacy of acarbose in the treatment of patients with non-insulindependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 121:928-935, 1994
8. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-738, 1991
9. Coniff RF, Shapiro JA, Seaton TB, Bray GA: Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98:443-451, 1995
10. Coniff RF, Shapiro JA, Robbins D, Kleinfeld R, Seaton TB, Beisswenger P, McGill JB: Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 18:817-824, 1995
11. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A: Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17:20-29, 1994
12. Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, Schernthaner G: Effects of 8-wk α-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12:537-543, 1989
13. Coniff RF, Johnston PS, Knowles L, Krol A: Long-term effects of the α-glucosidase inhibitor miglitol (BAY m 1099) in NIDDM patients treated with maximum-dose sulfonylurea (Abstract). Diabetes 45 (Suppl. 2):221A, 1996
14. Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C: The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 20:687-691, 1997
15. Rowe DJF, Dawnay A, Watts GF: Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 27: 297-312, 1990
16. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes; a progressive disease. Diabetes 44: 1249-1258, 1995
17. Dasmahapatra A, Bale A, Raghuwanshi MP, Reddi A, Byrne W, Suarez S, Nash F, Varagiannis E, Skurnich JH: Incipient and overt diabetic nephropathy in African-Americans with NIDDM: Diabetes Care 17:297-304, 1994
18. Banerji, MA, Chaiken RL, Lebovitz HE: Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 44:466-470, 1995
19. Umpierrez GE, Clark WS, Steen MT: Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crisis. Diabetes Care 20:479-483, 1997
20. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Mannieri D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M: Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735-744, 1997